Recurrent ovarian cancer: Treatment with pegylated liposomal doxorubicin; a Westmead cancer care centre experience

Asia-Pacific Journal of Clinical Oncology

Volumn 6, Issue 1, 2010, Pages 66-73

  Dear, Rachel F ^a   Gao, Bo ^b   Harnett, Paul ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Westmead Cancer Care Centre   (Australia)

Author keywords

Liposomal doxorubicin; Platinum resistance; Recurrent ovarian cancer

Indexed keywords

CA 125 ANTIGEN; DOXORUBICIN; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; LOW DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 77951221128     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01263.x     Document Type: Article

References (13)

1. Greenlee R, Hill-Harmon M, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
2. Markman M, Rothman R, Hakes T. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991, 9:389-93.
3. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initital treatment with these compounds. Gynecol Oncol 1990, 36:207-11.
4. Gordon A, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave LG. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19:3312-22.
5. Pfisterer J, Plante M, Vergote I. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006, 24:4699-707.
6. Mutch D, Orlando M, Goss T. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007, 25:2811-18.
7. Rustin GJ, Quinn M, Thigpen T. Re: new guidelines to evaluate the response to treatment in solid tumours [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2004, 96:487-8.
8. Rustin G, Marples M, Nelstrop AE, Mahmoudie M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with a persistently elevated level. J Clin Oncol 2001, 19:4054-7.
9. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines). J Natl Cancer Inst 2000, 92:205-16.
10. Cancer therapy evaluation program, common terminology criteria for adverse events. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, National Cancer Institute, Version 3.0. DCTD, NCI, NIH, DHHS [Cited 22 December 2009.] Available from URL:
11. Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 2004, 93:699-701.
12. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001, 19:1266-74.
13. Penson RT, Dignan F, Seiden MV. Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol 2004, 94:427-35.